stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) Return on equity
BioNTech SE Sponsored ADR's return on equity over the twelve months to 30 September 2026 was −8.29%, down 2.3 percentage points from fiscal 2025 (−6.01%). Over the past ten years it has ranged from −79.2% (fiscal 2017) to 155.7% (fiscal 2021); the current reading is higher than 44% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −6.01% | (2.66) |
| FY2024 | −3.35% | (8.03) |
| FY2023 | 4.68% | (51.79) |
| FY2022 | 56.5% | (99.26) |
| FY2021 | 155.7% | 154.09 |
| FY2020 | 1.64% | 47.85 |
| FY2019 | −46.2% | (1.96) |
| FY2018 | −44.3% | 34.93 |
| FY2017 | −79.2% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | 138.1% |
| ASND Ascendis Pharma A/S compare | 118.4% |
| EXEL Exelixis, Inc. compare | 44.3% |
| BBIO BridgeBio Pharma, Inc. compare | 26.2% |
| GMAB Genmab A/S Sponsored ADR compare | 14.0% |
| INCY Incyte Corporation compare | 7.84% |
| ROIV Roivant Sciences Ltd. compare | −5.47% |
| BNTX BioNTech SE Sponsored ADR | −8.29% |
| INSM Insmed, Inc. compare | −72.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement